全球双特异性抗体市场规模、份额、趋势和成长分析报告（2026-2034年）

双特异性抗体市场预计将从 2025 年的 117.3 亿美元成长到 2034 年的 293.5 亿美元，2026 年至 2034 年的复合年增长率为 10.73%。

受免疫疗法和肿瘤学研究进展的推动，全球双特异性抗体市场正经历快速扩张。双特异性抗体能够同时结合两种不同的抗原，从而提供更具标靶性和更有效的治疗方案，尤其是在癌症治疗领域。癌症发生率的上升和对精准医疗需求的日益增长是推动市场成长的关键因素。

对生物技术研发和临床试验的大量投资正在加速新型双特异性抗体候选药物的开发。製药公司正与研究机构合作，以提高疗效并减少副作用。创新生物製药获得监管部门核准，进一步增强了市场信心，并拓宽了患者的治疗选择。

随着研发线产品顺利推动临床试验，未来前景十分光明。除癌症治疗外，双特异性抗体在自体免疫疾病和感染疾病等领域的应用也在探索之中。随着产能的扩大和抗体工程技术的进步，预计未来几年双特异性抗体市场将实现显着成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球双特异性抗体市场：依应用领域划分

• 市场分析、洞察与预测
• 癌症治疗
• 自体免疫疾病
• 感染疾病
• 移植排斥

第五章：全球双特异性抗体市场：按类型划分

• 市场分析、洞察与预测
• 基于IgG的双特异性抗体
• 基于ScFv的双特异性抗体
• 双特异性T细胞衔接抗体

第六章：全球双特异性抗体市场：依作用机制划分

• 市场分析、洞察与预测
• 直接细胞杀伤
• 免疫调节
• 细胞激素释放

第七章：全球双特异性抗体市场：依最终用途划分

• 市场分析、洞察与预测
• 製药公司
• 研究机构
• 临床研究机构

第八章：全球双特异性抗体市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 亚太其他地区
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Pfizer
  • Takeda Pharmaceutical
  • Roche
  • AbbVie
  • Eli Lilly
  • Bristol Myers Squibb
  • GSK
  • Genmab
  • Novartis
  • Regeneron Pharmaceuticals
  • Astellas Pharma
  • Merck
  • Xencor
  • Amgen
  • Sanofi

The Bispecific Antibody Market size is expected to reach USD 29.35 Billion in 2034 from USD 11.73 Billion (2025) growing at a CAGR of 10.73% during 2026-2034.

The global bispecific antibody market is witnessing rapid expansion driven by advancements in immunotherapy and oncology research. Bispecific antibodies are designed to bind two different antigens simultaneously, offering targeted and more effective treatment options, particularly in cancer therapy. Rising cancer prevalence and increasing demand for precision medicine are major contributors to market growth.

Significant investments in biotechnology research and clinical trials have accelerated the development of novel bispecific antibody candidates. Pharmaceutical companies are collaborating with research institutions to enhance therapeutic efficacy and reduce side effects. Regulatory approvals of innovative biologics have further strengthened market confidence and expanded treatment options for patients.

Future prospects remain highly positive as pipeline products continue to advance through clinical stages. Applications beyond oncology, including autoimmune and infectious diseases, are being explored. With expanding manufacturing capabilities and technological progress in antibody engineering, the bispecific antibody market is expected to achieve substantial growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Cancer Treatment
• Autoimmune Disorders
• Infectious Diseases
• Transplant Rejection

By Type

• IgG-based Bispecific Antibodies
• ScFv-based Bispecific Antibodies
• Bispecific T-cell Engager Antibodies

By Mechanism of Action

• Direct Cell-killing
• Immune Modulation
• Cytokine Release

By End-Use

• Pharmaceutical Companies
• Research Institutions
• Clinical Research Organizations

COMPANIES PROFILED

• Pfizer, Takeda Pharmaceutical, Roche, AbbVie, Eli Lilly, Bristol Myers Squibb, GSK, Genmab, Novartis, Regeneron Pharmaceuticals, Astellas Pharma, Merck, Xencor, Amgen, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BISPECIFIC ANTIBODY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Cancer Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Autoimmune Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Transplant Rejection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BISPECIFIC ANTIBODY MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. IgG-based Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. ScFv-based Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Bispecific T-cell Engager Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BISPECIFIC ANTIBODY MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Mechanism Of Action
• 6.2. Direct Cell-killing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Immune Modulation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cytokine Release Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BISPECIFIC ANTIBODY MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Clinical Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BISPECIFIC ANTIBODY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Application
  • 8.2.2 By Type
  • 8.2.3 By Mechanism Of Action
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Application
  • 8.3.2 By Type
  • 8.3.3 By Mechanism Of Action
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Application
  • 8.4.2 By Type
  • 8.4.3 By Mechanism Of Action
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Application
  • 8.5.2 By Type
  • 8.5.3 By Mechanism Of Action
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Application
  • 8.6.2 By Type
  • 8.6.3 By Mechanism Of Action
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BISPECIFIC ANTIBODY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer
  • 10.2.2 Takeda Pharmaceutical
  • 10.2.3 Roche
  • 10.2.4 AbbVie
  • 10.2.5 Eli Lilly
  • 10.2.6 Bristol Myers Squibb
  • 10.2.7 GSK
  • 10.2.8 Genmab
  • 10.2.9 Novartis
  • 10.2.10 Regeneron Pharmaceuticals
  • 10.2.11 Astellas Pharma
  • 10.2.12 Merck
  • 10.2.13 Xencor
  • 10.2.14 Amgen
  • 10.2.15 Sanofi